Thursday saw a significant surge in Summit Therapeutics stock following the success of its experimental cancer drug, surpassing the performance of Merck's popular drug Keytruda. This outcome has raised eyebrows in the pharmaceutical industry. The results suggest that Summit's drug has the potential to outperform Keytruda, a major player in the market. The unexpected success has made investors bullish on Summit Therapeutics, causing a surge in its stock value. However, not all parties are convinced of the drug's superiority over Keytruda. This development could potentially shake up the current landscape of cancer treatment.